| Literature DB >> 35884181 |
Nanett Kvist Nikolaisen1,2, Mette Fertner2, Desiree Corvera Kløve Lassen3, Chaza Nazih Chehabi1, Amir Atabak Ronaghinia2,4, Mariann Chriél3, Vibeke Frøkjær Jensen3, Lars Bogø Jensen1, Karl Pedersen5, Tina Struve2.
Abstract
Antibiotic consumption is considered to be a main driver of antibiotic resistant bacteria. Mink breeding follows a distinctive seasonal reproduction cycle, and all of the mink produced in the northern hemisphere are bred, born, and pelted around the same time of year. Some of the diseases are age-related, which is reflected in the seasonal variation of antibiotic consumption. The seasonality makes mink a good model for the investigation of the association between antibiotic consumption and resistance. The objectives of this study were (1) to monitor the farm level of antibiotic resistance during one production cycle and (2) to assess the potential associations between antibiotic consumption and resistance. Twenty-four farms were included in this study (Denmark n = 20, Iceland n = 2, and The Netherlands n = 2), following a cohort of animals born in 2018. Staphylococcus delphini and Escherichia coli were isolated from samples of the carcasses and faeces and were collected randomly. The isolates were susceptibility tested and subsequently divided into the sensitive wildtype (WT) and the resistant non-wildtype (NWT) populations. The antibiotic consumption relative to the sampling periods was assessed as having a short-term or a long-term impact, i.e., in two explanatory factors. For both S. delphini and E. coli, a large between-farm variation of NWT profiles was detected. In the final multivariable, generalized linear mixed models, significant associations between NWT isolates and the consumption of specific antibiotics were found: the short-term use of tetracyclines in the growth period was associated with the occurrence of tetracycline NWT E. coli in the growth period (OR: 11.94 [1.78; 89.28]), and the long-term use of macrolide and tetracyclines was associated with the occurrence of erythromycin NWT S. delphini in the weaning period (OR: 18.2 [2.26; 321.36]) and tetracycline NWT S. delphini in the growth period (OR: 8.2 [1.27; 63.31]), respectively. Farms with zero consumption in the study years prior to sampling also had a substantial proportion of NWT isolates, indicating that NWT isolates are persistent and/or widely spread in the environment. Generally, a high occurrence of tetracycline NWTs was observed. NWT isolates with resistance against the most commonly used antibiotics were found on all the farms, stressing the need for routine surveillance and the prudent use of antibiotics. The results offer a preview of the complex relationship between consumption and resistance, demonstrating some significant associations between use and resistance. Moreover, antibiotic-resistant bacteria are present even on farms with no antibiotic consumption over extended periods, and theoretical explanations supported by the data are offered.Entities:
Keywords: Escherichia coli; Staphylococcus delphini; antibiotic consumption; antibiotic resistance; epidemiology
Year: 2022 PMID: 35884181 PMCID: PMC9311663 DOI: 10.3390/antibiotics11070927
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Antibiotic usage on mink farms (DK n = 20) during three short-term periods of the study period, 2018–2019. Number of mink farms with short-term consumption of the respective antibiotics (ABU), in the period just prior to the three sampling periods; weaning ABU (16 April–30 June), growth ABU (1 July–26 October), and breeding ABU (27 October 2018–25 March 2019). Other: Lincomycin in combination with spectinomycin; sulfamethoxazole in combination with trimethoprim, amphenicols, and aminoglycosides.
Figure 2Total antibiotic consumption in 2018 on the included farms (DK n = 20, IS n = 2, NL n = 2). DADD: defined daily animal dose, the assumed average dose needed to treat a 1 kg animal; biomass days calculated as in Jensen et al. [16]. Farms 1 and 2 are Dutch (orange). Farms 23 and 24 are Icelandic (blue). Green farms are Danish.
Staphylococcus delphini isolates from Danish mink farms collected during three sampling rounds from 2018–2019.
| Sampling Round | Number of Feed | Number of Farms | Total | Number of Isolates per Farm Mean (Range) | Proportion of Non-Wildtype Isolates at Farm Level | ||
|---|---|---|---|---|---|---|---|
| Benzylpenicillin | Erythromycin | Tetracycline | |||||
|
| 3 | 20 | 225 | 11 (10; 18) | 0.20 [0.07; 0.40] | 0.20 [0.00; 0.45] | 0.35 [0.20; 0.85] |
|
| 3 | 18 | 161 | 9 (4; 10) | 0.20 [0.00; 0.30] | 0.00 [0.00; 0.59] | 0.65 [0.25; 0.90] |
|
| 3 | 16 | 157 | 10 (7; 10) | 0.15 [0.00; 0.33] | 0.20 [0.00; 0.63] | 0.60 [0.28; 0.87] |
Weaning: bacterial sampling in June 2018. Growth: bacterial sampling in October 2018. Breeding: bacterial sampling in March 2019.
Antibiotic non-wildtype among Staphylococcus delphini isolates from Danish mink from 2018–2019. Association between antibiotic non-wildtype isolates and short-term use of the respective antibiotic drug on farm just prior to sampling (χ2-test results).
| Benzylpenicillin | Erythromycin | Tetracycline | ||||
|---|---|---|---|---|---|---|
| Prevalence of Non-Wildtype | Association with PEN Use | Prevalence of Non-Wildtype | Association with MAK Use | Prevalence | Association with TET Use | |
|
| 52/225 (0.23) | 75/225 (0.33) | 108/225 (0.48) | |||
|
| 39/161 (0.24) | 41/161 (0.25) | 96/161 (0.60) | |||
|
| 34/157 (0.22) | 56/157 (0.36) | No use | 89/157 (0.57) | No use | |
Weaning: bacterial sampling in June 2018, antibiotic use 16 April–30 June. Growth: bacterial sampling in October 2018, antibiotic use 1 July–26 October. Breeding: bacterial sampling in March 2019, antibiotic use 27 October 2018–25 March 2019. PEN: penicillins, MAK: macrolides, TET: tetracyclines.
Final multivariable, generalized linear mixed models with binomial outcomes of wildtype/non-wildtype of Staphylococcus delphini isolates, against one of three antibiotics (penicillins, macrolides, tetracyclines).
| Benzylpenicillin Non-Wildtype Isolates | Erythromycin Non-Wildtype Isolates | Tetracycline Non-Wildtype Isolates | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| ||
| Intercept | 1.50 (0.40) | 1.66 (0.46) | 1.79 (0.49) | 2.35 (1.31) | 4.23 (3.27) | 1.16 (1.28) | 0.12 (1.17) | 2.07 (0.00) | −0.18 (0.95) | |
| Random effects | Farm | 1.25 | 1.39 | 1.41 | 1.65 | 3.14 | 2.54 | 1.47 | 1.35 | 0.59 |
| Feed producer | 0.30 | 0.00 | 0.00 | 1.86 | 4.37 | 1.78 | 1.89 | 1.22 | 1.57 | |
| Short-term antibiotic use | - | - | - | - | - | - | - | - | - | |
| Long-term antibiotic use | - | - | - | 0.009 | - | - | - | 0.030 | - | |
| 0 (reference) 1 | 0 (reference) 1 | |||||||||
| Estimate (Std Error) | 2.90 (1.12) | 2.07 (0.00) | ||||||||
| OR [CI95%] | 18.2 [2.26;321.36] | 8.2 [1.27;63.31] | ||||||||
Weaning: bacterial sampling in June 2018, antibiotic use short-term, 16 April–30 June. Growth: bacterial sampling in October 2018, antibiotic use short-term, 1 July–26 October. Breeding: bacterial sampling in March 2019, antibiotic use short-term, 27 October 2018–25 March 2019. Long-term antibiotic use, from 2016 up until sampling. 1 No use of antibiotics has been used as reference: non-significant predictors not included in the final model.
Escherichia coli isolates from Danish mink farms collected during two sampling rounds in 2018.
| Sampling Round | Number of Farms | Total Number of Isolates | Number of Isolates per Farm | Proportion of Non-Wildtype Isolates at Farm Level Mean (Range) | |||
|---|---|---|---|---|---|---|---|
| Amoxiclav | Ampicillin | Tetracycline | |||||
|
| 3 | 20 | 194 | 9.7 (6; 10) | 0.02 (0.0; 0.11) | 0.25 (0.0; 0.70) | 0.27 (0.10; 0.70) |
|
| 3 | 18 | 180 | 9.5 (4; 11) | 0.09 (0.0; 0.40) | 0.47 (0.20; 0.90) | 0.28 (0.00; 0.75) |
Weaning: bacterial sampling in June 2018. Growth: bacterial sampling in October 2018. Amoxiclav: Amoxicillin in combination with clavulanic acid (1:2).
Non-wildtype Escherichia coli isolates from Danish mink farms collected during two sampling rounds in 2018. Association between resistance and short-term use of the respective antibiotic drug on farm just prior to sampling (χ2/fisher-test results).
| Amoxiclav Non-Wildtype | Ampicillin Non-Wildtype | Tetracycline Non-Wildtype | ||||
|---|---|---|---|---|---|---|
| Prevalence | Association with PEN Use | Prevalence | Association with PEN Use | Prevalence | Association with TET Use | |
|
| 5/194 (0.03) | 0.229 | 48/194 (0.25) | 1 | 53/194 (0.27) | 0.564 |
|
| 16/180 (0.09) | <0.001 | 85/180 (0.47) | 0.433 | 47/180 (0.26) | 0.244 |
Weaning: bacterial sampling in June 2018, antibiotic use 16 April–30 June. Growth: bacterial sampling in October 2018, antibiotic use 1 July–26 October. Amoxiclav: Amoxicillin in combination with clavulanic acid (1:2), PEN: penicillins, TET: tetracyclines.
Final multivariable generalized linear mixed models with binomial outcomes of wildtype/non-wildtype of Escherichia coli isolates. Amoxiclav and ampicillin non-wildtype tested against the use of penicillins; tetracycline non-wildtype tested against the use of tetracyclines.
| Amoxiclav Non-Wildtype | Ampicillin Non-Wildtype | Tetracycline Non-Wildtype | |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| Intercept | 3.63 (0.45) | 2.66 (0.46) | 1.20 (0.23) | 0.18 (0.27) | 0.99 (0.18) | −1.34 (0.39) | |
| Random effects | Farm | 2 × 10−7 | 0.94 | 0.59 | 0.39 | 0.26 | 0.29 |
| Feed producer | 0.00 | 0.00 | 0.00 | 0.32 | 0.00 | 0.25 | |
| Short-term antibiotic use | - | - | - | - | - | 0.013 | |
| 0 (reference) 1 | |||||||
| Estimate (Std Error) | 2.48 (0.92) | ||||||
| OR [CI95%] | 11.94 [1.78;89.28] | ||||||
| Long-term antibiotic use | - | - | - | - | - | - | |
Weaning: bacterial sampling in June 2018, antibiotic use short-term, 16 April–30 June. Growth: bacterial sampling in October 2018, antibiotic use short-term, 1 July–26 October. Long-term antibiotic use: from 2016 up until sampling. Amoxiclav: amoxicillin in combination with clavulanic acid (1:2). 1 No use of antibiotics has been used as reference: non-significant predictors not included in the final model.
Antibiotic non-wildtype among Staphylococcus delphini and Escherichia coli isolated from Danish mink from 2018–2019. Association between the proportions of antibiotic non-wildtype isolates and affiliated feed producers (χ2−/Fisher’s exact-test results).
| FP A | FP B | FP C | |||
|---|---|---|---|---|---|
|
| Tetracycline | 0.13 | 0.85 | 0.36 | <0.001 |
| Erythromycin | 0.63 | 0.08 | 0.38 | <0.001 | |
| Benzylpenicillin | 0.09 | 0.36 | 0.20 | <0.001 | |
|
| Amoxiclav | 0.03 | 0.03 | 0.03 | 1 |
| Ampicillin | 0.18 | 0.25 | 0.28 | 0.44 | |
| Tetracycline | 0.25 | 0.33 | 0.23 | 0.37 |
Amoxiclav: amoxicillin in combination with clavulanic acid (1:2), FP: feed producer.
Non-wildtypes (NWTs) of Staphylococcus delphini isolates from the weaning, growth, and breeding samplings in Denmark (n = 543).
| Antibiotic | (Antibiotic Group) | No. of NWT Isolates |
|---|---|---|
| Tetracycline | (tetracyclines) | 293 |
| Erythromycin | (macrolides) | 172 |
| Sulfamethoxazole | (sulfonamides) | 135 |
| Benzylpenicillin | (penicillins) | 125 |
| Streptomycin | (aminoglycosides) | 108 |
| Trimethoprim | (trimethoprim) | 79 |
| Spectinomycin | (aminocyclitol *) | 25 |
| Sulfa + TMP | (combination drug) | 7 |
| Tiamulin | (pleuromutilin) | 6 |
| Cefoxithin | (3rd gen. cephalosporin) | 4 |
| Florfenicol | (amphenicol) | 3 |
| Gentamicin | (aminoglycoside) | 2 |
| Chloramphenicol | (amphenicol) | 2 |
| Ciprofloxacin | (flouroquinolones) | 1 |
Weaning: bacterial sampling in June 2018. Growth: bacterial sampling in October 2018. Breeding: bacterial sampling in March 2019. Sulfa + TMP: Sulfamethoxazole in combination with trimethroprim (19:1). * Spectinomycin is closely related to the aminoglycosides.
Non-wildtypes (NWT) of Escherichia coli isolates from the weaning and growth samplings in Denmark (n = 374).
| Antibiotic | (Antibiotic Group) | No. of NWT Isolates |
|---|---|---|
| Ampicillin | (penicillins) | 133 |
| Trimethoprim | (trimethoprim) | 133 |
| Tetracycline | (tetracyclines) | 100 |
| Streptomycin | (aminoglycosides) | 100 |
| Sulfamethoxazole | (sulfonamides) | 95 |
| Spectinomycin | (aminoglycosides) | 47 |
| Ciprofloxacin | ((flouro-)quinolones) | 47 |
| Nalidixic acid | (quinolones) | 26 |
| Amoxiclav | (penicillins) | 21 |
| Chloramphenicol | (amphenicols) | 20 |
| Ceftiofur | (3rd gen. cephalosporins) | 17 |
| Florfenicol | (amphenicols) | 5 |
| Colistin | (polymyxins) | 5 |
| Neomycin | (aminoglycosides) | 3 |
| Gentamicin | (aminoglycosides) | 2 |
| Cefotaxime | (3rd gen. cephalosporins) | 2 |
| Apramycin | (aminoglycosides) | 0 |
Weaning: bacterial sampling in June 2018. Growth: bacterial sampling in October 2018. Amoxicillin in combination with clavulanic acid (2:1).
Figure 3Timeline of the study and production cycle. Vertical lines indicate the sampling of animals and faeces. X indicates another important time point in the production periods: whelping in May and pelting in November. ABU: antibiotic use.